MariaE.ArcilaMD

PubMed

• 185 citations
  DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
  Min Yuen Teo, Richard Martin Bambury, Emily C. Zabor, Emmet Jordan, Hikmat Al-Ahmadie
  Clinical Cancer Research. 2017-01-30
• 90 citations
  Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
  Gopa Iyer, Arjun Vasant Balar, Matthew I. Milowsky, Bernard H. Bochner, Guido Dalbagni
  Journal of Clinical Oncology. 2018-05-09
• 166 citations
  Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
  Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila
  Journal of Thoracic Oncology. 2021-10-01

Journal Articles

• Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a ...  
  Maria E.Arcila MD, Soo-Ryum Yhan BS, Daniela Elezovic BS, Ryma Benayed PhD, Ahmet Zehir PhD, Darren J. Buonocang, MDAmirMomeni MD, Douglas A. Mata MD, Paulo Salazar BS..., JTO Clinical and Research Reports Volume 1, Issue 3, September 2020, 100077, 9/2020
• Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
  Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature

Books/Book Chapters

• Genomic Medicine: A Practical Guide 
  Chapter: Lung Carcinoma 
  Page 83 - 102Maria ArcilaEditors: Maria Arcila, Laura Tafe.Springer International PublishingEdition 1st,2019
• Genomic Medicine: A Practical Guide 
  Chapter: Chronic Myeloid Neoplasms 
  Page 235 - 252Maria Arcila, Caleb HoEditors: Laura Tafe, Maria Arcila.Springer Edition 1st,2019

Abstracts/Posters

• Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis
  Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase
  Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a Spike-in Clonal Sequence
  Maria E Arcila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Molecular Diagnostics of Lymphoma: Classification, risk assessment and monitoring 
  USCAP course - A Primer in Precision Pathology: Genomics, Al and Immuno-Oncology - 3/21/2022
• IASLC Hot Topics 2020: Liquid biopsy 
  Worldwide Virtual Event - 10/2/2020
• Virtual Tumor Board®: Global Perspectives on Comprehensive NGS Profiling to Personalize Treatment in Cancer 
  8/14/2020
• What Are the Types of Tumor Testing (Technologies IHC vs FISH vs NGS vs WES) 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• NGS based clonality testing: Assessing clonality status, somatic hypermutation and residual disease 
  http://www.amp.org/education/OCWattendees.cfm. - 10/10/2017
• Join now to see all